Literature DB >> 19430863

Therapy related CMML: a case report and review of the literature.

Faheem Ahmed1, Nadia Osman, Fred Lucas, Guy Neff, Teresa Smolarek, John M Bennett, Rami S Komrokji.   

Abstract

Therapy related chronic myelomonocytic leukemia (t-CMML) is rare. We report a 23-year-old female who developed acute fulminant hepatic failure after drug overdose. She underwent ABO incompatible orthotopic liver transplant. She received cyclophosphamide along with other immunosuppressants. Seven years later, she was diagnosed with t-CMML-2 with 45XX,-7 karyotype. She received 4 cycles of azacitidine and proceeded with allogeneic bone marrow transplant. This is the first a case of t-CMML reported in a liver transplant recipient. In this article, we also summarize all reported cases of t-CMML, and we review therapy related MDS in recipients of solid organ transplant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430863     DOI: 10.1007/s12185-009-0318-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  16 in total

1.  Therapy-related chronic myelomonocytic leukaemia with bone marrow eosinophilia associated with der(11)t(1;11)(q21;q14).

Authors:  K Muroi; T Miyata; M Saito; K Hatake; Y Amemiya; Y Miura
Journal:  Acta Haematol       Date:  1996       Impact factor: 2.195

2.  Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature.

Authors:  K B Kim; S Faderl; C S Hwang; F R Khuri
Journal:  J Clin Pharm Ther       Date:  2006-08       Impact factor: 2.512

Review 3.  The clinical implications of the World Health Organization's classification of myelodysplastic syndromes.

Authors:  Rami S Komrokji; John M Bennett
Journal:  Curr Hematol Rep       Date:  2005-05

4.  Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation.

Authors:  Guido Kobbe; Ulrich Germing; Manuel Aivado; Fabian Zohren; Dominik Schubert; Corinna Strupp; Hildegard Pape; Gero Tenderich; Reiner Körfer; Rainer Storb; Rainer Haas; Peter Schneider
Journal:  Transplantation       Date:  2002-10-27       Impact factor: 4.939

Review 5.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

Review 6.  Two different classes of therapy-related and de-novo acute myeloid leukemia?

Authors:  J Pedersen-Bjergaard; P Philip
Journal:  Cancer Genet Cytogenet       Date:  1991-08

7.  Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation.

Authors:  Judith Offman; Gerhard Opelz; Bernd Doehler; David Cummins; Ozay Halil; Nicholas R Banner; Margaret M Burke; Dianne Sullivan; Peter Macpherson; Peter Karran
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

8.  ABO-incompatible liver transplantation with no immunological graft losses using total plasma exchange, splenectomy, and quadruple immunosuppression: evidence for accommodation.

Authors:  Douglas W Hanto; Annie H Fecteau; Maria H Alonso; John F Valente; James F Whiting
Journal:  Liver Transpl       Date:  2003-01       Impact factor: 5.799

9.  An approach to ABO-incompatible liver transplantation in children.

Authors:  T H Renard; W S Andrews
Journal:  Transplantation       Date:  1992-01       Impact factor: 4.939

10.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

View more
  6 in total

1.  Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.

Authors:  Norio Asou; Eisaku Iwanaga; Tomoko Nanri; Hiroaki Mitsuya
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

2.  Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.

Authors:  Koichi Takahashi; Naveen Pemmaraju; Paolo Strati; Graciela Nogueras-Gonzalez; Jing Ning; Carlos Bueso-Ramos; Rajyalakshmi Luthra; Sherry Pierce; Jorge Cortes; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113

Review 3.  A focused review of hematopoietic neoplasms occurring in the therapy-related setting.

Authors:  Liping Zhang; Sa A Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature.

Authors:  Elena Elli; Caterina Cecchetti; Angelo Belotti; Lorenza Borin; Enrico Maria Pogliani
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-03-13       Impact factor: 2.576

Review 5.  Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Authors:  Peter Valent; Attilio Orazi; Michael R Savona; Mrinal M Patnaik; Francesco Onida; Arjan A van de Loosdrecht; Detlef Haase; Torsten Haferlach; Chiara Elena; Lisa Pleyer; Wolfgang Kern; Tea Pemovska; Gregory I Vladimer; Julie Schanz; Alexandra Keller; Michael Lübbert; Thomas Lion; Karl Sotlar; Andreas Reiter; Theo De Witte; Michael Pfeilstöcker; Klaus Geissler; Eric Padron; Michael Deininger; Alberto Orfao; Hans-Peter Horny; Peter L Greenberg; Daniel A Arber; Luca Malcovati; John M Bennett
Journal:  Haematologica       Date:  2019-05-02       Impact factor: 9.941

6.  Cancer Incidence among Heart, Kidney, and Liver Transplant Recipients in Taiwan.

Authors:  Kwai-Fong Lee; Yi-Ting Tsai; Chih-Yuan Lin; Chung-Bao Hsieh; Sheng-Tang Wu; Hung-Yen Ke; Yi-Chang Lin; Feng-Yen Lin; Wei-Hwa Lee; Chien-Sung Tsai
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.